At 32.5%+ CAGR, Car T Cell Therapy Market will Reach US$ 7.7 Billion by 2028

Key players in the market are engaged in extensive research and development to launch new targeted cell therapies in the market. For instance, the University of Texas MD Anderson Cancer Center, Houston is conducting phase 1 clinical trial studies of central memory–derived CD19 CAR T–cell therapy for relapsed intermediate-grade B-cell non-Hodgkin lymphoma. Moreover, key players are focusing on strategic merger and acquisition to enhance their share in the global CAR-T cell therapy market. For instance, in April 2018, Pfizer, Inc. signed a deal with Allogene, to develop an investigational CAR-T cell therapy for treating cancer.

Request Sample

Key players operating in the global CAR-T cell therapy market include Novartis International AG, Kite Pharma, Inc. (Gilead Sciences, Inc.), Juno Therapeutics (Celgene Corporation), Bluebird Bio, Inc. (Celgene Corporation), Sorrento Therapeutics Inc., Mustang Bio, Inc., Aurora Biopharma Inc., Legend Biotech (Genscript Biotech Corporation), Pfizer, Inc., CARsgen Therapeutics, Ltd., and others.

CAR-T cell therapy is expected to be an important development in cancer treatment and therapeutics industry due to its cost efficiency. Moreover, rising incidence of cancer is leading to high demand for its treatment.

According to the World Cancer Research Fund International (WCRFI), around 14.1 million cancer cases were reported worldwide, in 2012. As per WCRFI, it is projected that by 2035, around 24 million cancer cases would be observed worldwide.

Moreover, introduction of new therapies into the market is further expected to bolster growth of CAR-T cell therapy market. For instance, in October 2017, the U.S. Food and Drug Administration granted marketing approval to Yescarta (axicabtagene ciloleucel), a cell-based gene therapy, to treat adult patients with certain types of large B-cell lymphoma.

CAR T cell therapy market is expected to be primarily driven by increasing demand for highly effective therapy mode of treating cancer. Combating cancer has been a major concern for healthcare industry for years.

CAR T cell works on gene transfer technology that boosts the immune response of cancer affected individual by destroying affected tumor cells. It has been analyzed to act as a lifesaving drug for over 30 million patients’ sufferings from lymphoma. Though the CAR T cell therapy market outlook is highly optimistic, market players need to address the manufacturing and scalability options to generate higher profits. Novartis and Kite have already started building a roadmap for it.

Talk To Analyst

Global CAR T Cell Therapy Market, By Targeted Antigen, Therapeutic Application, and Geography - Trends, Analysis and Forecast till 2028

CAR T cell therapy has been a major buzzword for a while, owing to its effectiveness in treating blood cancer. These are the genetically engineered receptors that targets surface molecules in patient’s immune system. T cells are collected from patients and are genetically engineered in the laboratory in order to multiply them by millions. These T cells are further injected in patients to offer immunity and guard against recurrence of tumorous cells.

Get Free PDF Research Brochure for more Professional and Technical Insights: https://www.coherentmarketinsights.com/insight/request-sample/102

Market Dynamics

CAR T cell therapy is expected to be a game changer post its commercialization creating revenue opportunities for players in the CAR T cell therapy market. Moreover, it is expected to help with effective diagnosis of acute lymphoblastic leukemia (ALL) in B cells of children. Introduction of the drug is expected to be especially beneficial for leukemia patients. According to the U.S. National Cancer Institute, over 340,000 people in the U.S., suffered from leukemia in 2015, with an estimated 1.5% of the population in the country expected to be detect with leukemia once in their lifetime. Growing prevalence rate and increasing demand for effective treatment modalities is expected to pave way for market growth over the forecast period.

The CAR T cell therapy market is expected to be highly consolidated over the next few years, with the three major players accounting for around half of the overall market revenue share. This novel therapeutic application is expected to create lucrative profit margins for industry players across the value chain, ranging from manufacturers to distributors and end-use hospitals.

Market Taxonomy

This report segments the CAR T cell therapy market on the basis of antigen type, and therapeutic applications. On the basis of antigen, CAR T cell therapy market is segmented as CD 19, CD 20, GD2, CD22, CD30, CD33, HER1, HER2, Meso, EGFRvlll, and others.

Browse Global Strategic Business Report : https://www.coherentmarketinsights.com/market-insight/car-t-cell-therapy-market-102

On the basis of therapeutic applications, CAR T cell therapy market is segmented into acute lymphocytic leukemia, chronic lymphocytic leukemia, non-hodgkin leukemia, multiple myeloma, pancreatic cancer, neuroblasta, breast cancer, acute myeloid leukemia, hepatocellular carcinoma, colorectal cancer, and other therapeutic applications.

Key features of the study:

• This report provides in-depth analysis of the CAR T cell therapy market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR) (%) for the forecast period (2017 – 2028)
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
• This study also provides valuable insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
• The report takes into account critical limiting factors such as accuracy issues and need for calibrating the device several times a day while analyzing the market value and growth (%) during the forecast period
• It includes insights on population dynamics, number of dental clinic centers, and demand for CAR T Cell Therapy across the globe.
• It profiles leading players in the global CAR T Cell Therapy market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies and future plans
• Key companies covered as a part of this study include Juno Therapeutics, Kite Pharma Inc., Novartis International AG, Bellicum Pharmaceuticals Inc., Celgene Corporation, and Cellectis.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions with respect to their future product launch, technology upgrade, market expansion, and marketing tactics
• The global CAR T Cell Therapy market report caters to various stakeholders in this industry, including investors, raw material manufacturer, contract manufacturer, device manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would greatly benefit in decision making through the various strategy matrices used in analyzing the CAR T Cell Therapy market.

ABOUT US

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Global CAR T Cell Therapy Market to Reach US$ 8.5 Billion by 2028 : Coherent Market Insights

The Global Car T Cell Therapy Market is expected to be valued at US$ 8.5 Billion by 2028, as analyzed by Coherent Market Insights. Increasing demand for genetically engineered treatment approach for high success rate in cancer treatment along with growing cancer incidence rate are key factors driving demand for CAR T cell therapy products worldwide.

Get Free PDF Research Brochure for more Professional and Technical Insights : https://www.coherentmarketinsights.com/insight/request-sample/102

Lately, CAR T cell therapy has emerged as the new pillar for cancer treatment, creating high market potential for companies engaged in development and promotion of the product. Currently, Novartis International AG, Juno Therapeutics and Kite Pharma Inc. are dominating the CAR T cell therapy market. Clinical research by these players have revealed high rate of remission in patients with r/r B cell ALL and DLBCL. These companies are making major investments in R&D to expedite the clinical process. Novartis invested around US$ 9 billion in R&D – significant share of it is allocated towards oncology and development of CAR-T cell products in 2016. This novel cellular immunotherapy has attracted significant investment in last two years.

CAR T cell therapy market is expected to be primarily driven by increasing demand for highly effective therapy mode of treating cancer. Combating cancer has been a major concern for healthcare industry for years. CAR T cell works on gene transfer technology that boosts the immune response of cancer affected individual by destroying affected tumor cells. It has been analyzed to act as a lifesaving drug for over 30 million patients’ sufferings from lymphoma. Though the CAR T cell therapy market outlook is highly optimistic, market players need to address the manufacturing and scalability options to generate higher profits. Novartis and Kite have already started building a roadmap for it.

Key takeaways of the market are:

• North America is expected to dominate the CAR T cell therapy market throughout the forecast period. The region is expected to account for 58.3% of overall industry share by 2018. Leukemia, lymphoma, and myeloma accounted for 9.4% of 1.6 million newly diagnosed cancer in 2015. Each year, around 55 thousand people die due to leukemia, lymphoma and myeloma in U.S. Emergence of CAR T cell therapy is expected to address the blood cancer concerns. Mortality rate is expected to be drastically lower by 2020 with the adoption of this novel treatment approach.

• Europe is expected to be the second largest market for CAR T cell therapy products manufacturers. Although, the region is expected to create lucrative market opportunities, conducting country-specific clinical trials across Europe is expected to be a cumbersome process for companies and is a key challenge for growth prospects in the region.

• CD 19 based therapy segment is expected to dominate the global CAR T cell therapy market revenue throughout the forecast period. CD 19 segment is expected to touch a billion dollar mark by 2023. Much of the companies are working on CD 19 to combat leukemia. Other antigens such as CD 20 and CD 22 are also expected to create significant revenue opportunity for treatment of solid tumors.

• At present, Novartis International AG and Kite Pharma Inc. are expected to launch their products in 2017. Juno Therapeutics is expected to commercialize its product by 2018. Besides these players, Bellicum Pharmaceutical, Celgene Corporation, and Cellectisare also engaged in R&D process and are focusing on curtailing time-to-market for their product to capitalize the market potential in the following 10 years.

ABOUT US

COMPANY OVERVIEW

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. We are uniquely positioned to help businesses around the globe deliver practical and lasting results through various recommendations about operational improvements, technologies, emerging market trends and new working methods. We offer both customized and syndicated market research reports that help our clients create visionary growth plans to provide traction to their business. We meticulously study emerging trends across various industries at both the global and regional levels to identify new opportunities for our clientele. Our global team of over 100 research analysts and freelance consultants provide market intelligence from the very molecular country level and also provide a global perspective of the market. Our team is of the most vital cog in our robust machinery that gives us the ability to deliver independent insight relying on our cognitive defusion training module.This allows for an objective and unbiased assessment of the market. We pride ourselves in my constantly striving to update our extremely in-depth understanding of the market by closely monitoring and analyzing markets, trends, and emerging best practices, across allfathomable industries under the sun. This enables us to equip our valued clientele with key decisive inputs to capitalize on lucrative growth opportunities in the market and to follow firmly position themselves on a high growth path in the future.